Literature DB >> 17008533

Expression of a bcr-1 isoform of RARalpha-PML does not affect the penetrance of acute promyelocytic leukemia or the acquisition of an interstitial deletion on mouse chromosome 2.

Matthew J Walter1, Rhonda E Ries, Jon R Armstrong, John S Park, Elaine R Mardis, Timothy J Ley.   

Abstract

Expression of a bcr-3 isoform of retinoic acid receptor alpha-promyelocytic leukemia (RARalpha-PML) in mice expressing a bcr-1 isoform of PML-RARalpha is associated with increased penetrance of murine acute promyelocytic leukemia (APL) and the frequent acquisition of an interstitial deletion of one copy of mouse chromosome 2 (del(2)). To determine whether the isoform of RARalpha-PML is important for these effects, we created mice that expressed a bcr-1 isoform of RARalpha-PML. Coexpression with the bcr-1 isoform of PML-RARalpha did not increase the penetrance of APL (7 of 45 animals developed APL with PML-RARalpha alone vs 12 of 44 with both transgenes; P=.19). Furthermore, the frequency of del(2) in APL cells from doubly transgenic mice was not different from that of mice expressing PML-RARalpha alone (3 of 6 vs 6 of 12, respectively-P=1.38-compared with 11 of 11 for mice coexpressing PML-RARalpha and bcr-3 RARalpha-PML). The bcr-1 and bcr-3 isoforms of RARalpha-PML, therefore, have different biological activities that may be relevant for the pathogenesis of murine APL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008533      PMCID: PMC1785146          DOI: 10.1182/blood-2006-07-037465

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Assembly of microarrays for genome-wide measurement of DNA copy number.

Authors:  A M Snijders; N Nowak; R Segraves; S Blackwood; N Brown; J Conroy; G Hamilton; A K Hindle; B Huey; K Kimura; S Law; K Myambo; J Palmer; B Ylstra; J P Yue; J W Gray; A N Jain; D Pinkel; D G Albertson
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

2.  Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha.

Authors:  Matthew J Walter; John S Park; Rhonda E Ries; Steven K M Lau; Michael McLellan; Sara Jaeger; Richard K Wilson; Elaine R Mardis; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-19       Impact factor: 11.205

3.  Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia.

Authors:  Michelle M Le Beau; Elizabeth M Davis; Bhumi Patel; Vernon T Phan; Jastinder Sohal; Scott C Kogan
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia.

Authors:  J L Pollock; P Westervelt; A K Kurichety; P G Pelicci; J L Grisolano; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.

Authors:  D B Zimonjic; J L Pollock; P Westervelt; N C Popescu; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

6.  Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

Authors:  S De Botton ; S Chevret; M Sanz; H Dombret; X Thomas; A Guerci; M Fey; C Rayon; F Huguet; J J Sotto; C Gardin; P Cony Makhoul ; P Travade; E Solary; N Fegueux; D Bordessoule; J San Miguel ; H Link; B Desablens; A Stamatoullas; E Deconinck; K Geiser; U Hess; F Maloisel; S Castaigne; C Preudhomme; C Chomienne; L Degos; P Fenaux
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

Review 7.  Characterization of genetic instability in radiation- and benzene-induced murine acute leukemia.

Authors:  K Rithidech; J J Dunn; V P Bond; C R Gordon; E P Cronkite
Journal:  Mutat Res       Date:  1999-07-16       Impact factor: 2.433

8.  Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia.

Authors:  Nirosha Suraweera; Emmy Meijne; John Moody; Luis G Carvajal-Carmona; Kazuko Yoshida; Patrick Pollard; Jude Fitzgibbon; Andrew Riches; Theo van Laar; Rene Huiskamp; Andrew Rowan; Ian P M Tomlinson; Andrew Silver
Journal:  Oncogene       Date:  2005-05-19       Impact factor: 9.867

9.  Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.

Authors:  Frank Rosenbauer; Katharina Wagner; Jeffery L Kutok; Hiromi Iwasaki; Michelle M Le Beau; Yutaka Okuno; Koichi Akashi; Steven Fiering; Daniel G Tenen
Journal:  Nat Genet       Date:  2004-05-16       Impact factor: 38.330

10.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia.

Authors:  Beatrice U Mueller; Thomas Pabst; Motomi Osato; Norio Asou; Lisa M Johansen; Mark D Minden; Gerhard Behre; Wolfgang Hiddemann; Yoshiaki Ito; Daniel G Tenen
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

View more
  2 in total

1.  Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice.

Authors:  John S Welch; Jeffery M Klco; Nobish Varghese; Rakesh Nagarajan; Timothy J Ley
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

2.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Authors:  John S Welch; Peter Westervelt; Li Ding; David E Larson; Jeffery M Klco; Shashikant Kulkarni; John Wallis; Ken Chen; Jacqueline E Payton; Robert S Fulton; Joelle Veizer; Heather Schmidt; Tammi L Vickery; Sharon Heath; Mark A Watson; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.